Pfizer Inc., the leading global pharmaceutical company, generates net sales primarily from primary care products (52.3%), specialty care products (25.6%), and oncology products (19.9%). Geographically, sales are distributed with 42.3% in the United States, 21.9% in Europe, and 33.8% in other regions. UBS has reiterated its Neutral rating on the company.